This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Ayush is expanding beyond wellness to therapeutic wellness
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Subscribe To Our Newsletter & Stay Updated
